Related Experiment Video
Updated: Dec 1, 2025
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Oncogenic State and Cell Identity Combinatorially Dictate the Susceptibility of Cells within Glioma Development
Anhao Tian1,2, Bo Kang3, Baizhou Li4
1Department of Neurosurgery of the Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310058 China.
Abstract:
Glioblastoma is the most malignant cancer in the brain and currently incurable. It is urgent to identify effective targets for this lethal disease. Inhibition of such targets should suppress the growth of cancer cells and, ideally also precancerous cells for early prevention, but minimally affect their normal counterparts. Using genetic mouse models with neural stem cells (NSCs) or oligodendrocyte precursor cells (OPCs) as the cells-of-origin/mutation, it is shown that the susceptibility of cells within the development hierarchy of glioma to the knockout of insulin-like growth factor I receptor (IGF1R) is determined not only by their oncogenic states, but also by their cell identities/states. Knockout of IGF1R selectively disrupts the growth of mutant and transformed, but not normal OPCs, or NSCs. The desirable outcome of IGF1R knockout on cell growth requires the mutant cells to commit to the OPC identity regardless of its development hierarchical status. At the molecular level, oncogenic mutations reprogram the cellular network of OPCs and force them to depend more on IGF1R for their growth. A new-generation brain-penetrable, orally available IGF1R inhibitor harnessing tumor OPCs in the brain is also developed. The findings reveal the cellular window of IGF1R targeting and establish IGF1R as an effective target for the prevention and treatment of glioblastoma.
Insights
Targeting the insulin-like growth factor I receptor (IGF1R) effectively suppresses glioblastoma growth by selectively affecting mutant cells. This discovery offers a promising new avenue for brain cancer prevention and treatment.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Glioblastoma is an aggressive, incurable brain cancer requiring novel therapeutic targets.
- Identifying targets that inhibit cancer growth while sparing normal cells is crucial for effective treatment and prevention.
Purpose of the Study:
- To investigate the efficacy of targeting the insulin-like growth factor I receptor (IGF1R) in glioblastoma.
- To determine the impact of IGF1R inhibition on both cancerous and normal neural stem cells (NSCs) and oligodendrocyte precursor cells (OPCs).
Main Methods:
- Utilized genetic mouse models with NSCs or OPCs as cells-of-origin for glioblastoma.
- Examined the effects of insulin-like growth factor I receptor (IGF1R) knockout on cell growth and identity.
- Developed a novel brain-penetrable, orally available IGF1R inhibitor.
Main Results:
- IGF1R knockout selectively inhibited the growth of mutant and transformed OPCs, but not normal OPCs or NSCs.
- The therapeutic effect of IGF1R knockout was dependent on mutant cells committing to an OPC identity.
- Oncogenic mutations reprogrammed OPCs to increase their dependency on IGF1R for growth.
Conclusions:
- The cellular identity, specifically OPC commitment, is critical for the selective efficacy of IGF1R targeting in glioblastoma.
- IGF1R is established as a viable therapeutic target for glioblastoma prevention and treatment.
- A new generation of IGF1R inhibitors shows potential for clinical application in brain tumors.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation